Загрузка...
First-line natalizumab in multiple sclerosis: rationale, patient selection, benefits and risks
Natalizumab (NTZ) is a highly effective disease modifying therapy for the treatment of relapsing forms of multiple sclerosis (MS). Despite evidence to support its use as first-line therapy, risk of NTZ-associated progressive multifocal leukoencephalopathy (PML) has largely contributed to it being re...
Сохранить в:
| Главные авторы: | , , , |
|---|---|
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
SAGE Publications
2014
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3926344/ https://ncbi.nlm.nih.gov/pubmed/24587891 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/2040622313514790 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|